Media Coverage

Filter by Year: 2017 2016 2015 2014 2013 2012
Bioshares Edition 692 - IIL Completes Dosing in Phase 2B MS Trial

Innate Immunotherapeutics has completed dosing the 93 patients participating
in its Phase IIb secondary progressive multiple sclerosis (SPMS) trial. Results are
now due in late August or early September with the possibility of earlier topline results.

Bioshares Edition 685 - Innate's Rollercoaster Share Price

Innate Immunotherapeutics' (IIL: $0.58) share price has been on a rollercoaster ride for the last two months. While its underlying business has been progressing to plan, its share price has become highly volatile, driven by trading on a US exchange which was initiated without the company's consent, a sell down in shares by a local investment fund, and post-US election political snitching that has been playing out through US and Australian print media...The fundamentals of the Innate business remain unchanged.

Bioshares Edition 680 - Innate Attracts Strong US Interest

Innate Immunotherapeutics (IIL) has seen its share price increase over the last five weeks, giving the company a market capitalisation of in the order of $300 million. The reason has been the heightened profile of the stock in the US (and as a result in Australia) through coverage in the New York Times and other news groups which have discussed interest in the stock from senior Republican politicians in the US. Buying of the stock by US investors has been facilitated through the stock trading on the OTC market in the US.

Gordon Capital Update Report - January 2017

Commercial Potential Drives Strong Market Support for MS Drug Treatment